drugset / Trial / NCT05549024
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Timeline
- Start
- 2022-08-16
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 3.7 mbq/kg | Intravenous |
| Subject | 18F-FDG | Diagnostic / imaging agent | 5.55 mbq/kg | Intravenous |
| Subject | 68Ga-RGD | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |
| Subject | 68Ga-RGD | Diagnostic / imaging agent | 2.2 mbq/kg | Intravenous |
| Subject | 68Ga-RM26 | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |
| Subject | 68Ga-RM26 | Diagnostic / imaging agent | 2.2 mbq/kg | Intravenous |
| Subject | 68Ga-RM26-RGD | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |
| Subject | 68Ga-RM26-RGD | Diagnostic / imaging agent | 2.2 mbq/kg | Intravenous |